Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for mo… Read more
Verrica Pharmaceuticals Inc (VRCA) - Total Liabilities
Latest total liabilities as of September 2025: $57.94 Million USD
Based on the latest financial reports, Verrica Pharmaceuticals Inc (VRCA) has total liabilities worth $57.94 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Verrica Pharmaceuticals Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Verrica Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Verrica Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Verrica Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guyoung Technology Co. Ltd
KQ:053270
|
Korea | ₩334.98 Billion |
|
PJ Electronics Co. Ltd
KQ:006140
|
Korea | ₩58.36 Billion |
|
Chengdu PUTIAN Telecommunications Cable Company Limited
F:CUEH
|
Germany | €160.02 Million |
|
Sri panwa Hospitality Real Estate Investment Trust
BK:SRIPANWA
|
Thailand | ฿718.68 Million |
|
Maniker F & G Co. Ltd
KQ:195500
|
Korea | ₩44.73 Billion |
|
Hermès International Société en commandite par actions
BE:HMI
|
Germany | €5.24 Billion |
|
Vroom, Inc. Common Stock
PINK:VRM
|
USA | $822.58 Million |
|
Jeilin Technology Co., Ltd.
TWO:8102
|
Taiwan | NT$131.51 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Verrica Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Verrica Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Verrica Pharmaceuticals Inc (2016–2024)
The table below shows the annual total liabilities of Verrica Pharmaceuticals Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $63.99 Million | +3.49% |
| 2023-12-31 | $61.83 Million | +1218.98% |
| 2022-12-31 | $4.69 Million | -90.13% |
| 2021-12-31 | $47.52 Million | +15.43% |
| 2020-12-31 | $41.17 Million | +1107.63% |
| 2019-12-31 | $3.41 Million | +37.63% |
| 2018-12-31 | $2.48 Million | -84.64% |
| 2017-12-31 | $16.12 Million | +402.62% |
| 2016-12-31 | $3.21 Million | -- |